From: 18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer
Week
Patients (responders/evaluable), n/N
Response Rate, %
4
4/38
11
8
9/38
24
12
12/37
32
16
14/32
44
20
10/28
36
10/21
48
28
9/17
53